HedgeChatter

  • Home /
  • Tag Archives

GRF

Annual Report for 2013 on Form 20-F filed with the SEC on April 4, 2014

[CNW Group] – Annual Report for 2013 on Form 20-F filed with the SEC on April 4, 2014 moreView todays social media effects on GRFView the latest stocks trending across Twitter. Click to view dashboardSee who Eagle is hiring next, click here to view […]

April 4, 2014 Bystocknews , Comments Off on Annual Report for 2013 on Form 20-F filed with the SEC on April 4, 2014 read more

Annual Report for 2012 on Form 20-F filed with the SEC on April 5, 2013

[PR Newswire] – BARCELONA, Spain, April 5, 2013 /PRNewswire/ — Grifols, S.A. (Grifols) (MCE:GRF, MCE:GRF.P and NASDAQ: GRFS), announced that it has filed its 2012 Annual Report on Form 20-F with the United … moreView todays social media effects on GRFView the latest stocks trending across Twitter. Click to view dashboardSee who Eagle is hiring next, click here to view […]

April 5, 2013 Bystocknews , Comments Off on Annual Report for 2012 on Form 20-F filed with the SEC on April 5, 2013 read more

Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection

[PR Newswire] – SAN DIEGO, March 6, 2013 /PRNewswire/ — Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products … moreView todays social media effects on GRFView the latest stocks trending across Twitter. Click to view dashboardSee who Eagle is hiring next, click here to view […]

March 7, 2013 Bystocknews , Comments Off on Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection read more

PROLASTIN® celebrates 25 years as leading augmentation therapy for treatment of alpha(1)-antitrypsin deficiency

[PR Newswire] – RESEARCH TRIANGLE PARK, N.C., Feb. 5, 2013 /PRNewswire/ — Grifols, a global healthcare company based in Barcelona, Spain, is commemorating the 25 th anniversary year of PROLASTIN ® (alpha 1 -proteinase … moreView todays social media effects on GRFView the latest stocks trending across Twitter. Click to view dashboardSee who Eagle is hiring next, click here to […]

February 5, 2013 Bystocknews , Comments Off on PROLASTIN® celebrates 25 years as leading augmentation therapy for treatment of alpha(1)-antitrypsin deficiency read more

Grifols’ shareholders approve bonus share issue as a remuneration formula

[at noodls] – Grifols holds its Extraordinary General Meeting of Shareholders, with over 76% of the company’s share capital represented Grifols shareholders approve a bonus share issue as a remuneration formula for … moreView todays social media effects on GRFView the latest stocks trending across Twitter. Click to view dashboardSee who Eagle is hiring next, click here to view […]

December 5, 2012 Bystocknews , Comments Off on Grifols’ shareholders approve bonus share issue as a remuneration formula read more

Eagle Capital Growth Fund Declares Year-End Dividend of $0.36 Per Share

[Business Wire] – The Eagle Capital Growth Fund, Inc. today declared a year-end cash dividend of $0.36 per share. The record date for this dividend is December 17, 2012, and moreView todays social media effects on GRFView the latest stocks trending across Twitter. Click to view dashboardSee who Eagle is hiring next, click here to view […]

December 3, 2012 Bystocknews , Comments Off on Eagle Capital Growth Fund Declares Year-End Dividend of $0.36 Per Share read more

Grifols’ sales increased by 14.4% to 1,959.5 million euros in the first nine months of 2012

[at noodls] – 92% of the group’s total sales generated in international markets Grifols’ sales increased by 14.4%1 to 1,959.5 million euros in the first nine months of 2012 ï‚· Net profit3 increases over 4 times, reaching … moreView todays social media effects on GRFView the latest stocks trending across Twitter. Click to view dashboard […]

November 7, 2012 Bystocknews , Comments Off on Grifols’ sales increased by 14.4% to 1,959.5 million euros in the first nine months of 2012 read more